$CNO

Tarasi Rocco F. III sold $450K of CNO

Tarasi Rocco F. III (Chief Marketing Officer) sold 9,058 shares of CNO Financial Group, Inc. (CNO) at an average of $49.63 ($49.00–$50.00, $0.45M total) across 2 trades over 2026-06-10 to 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tarasi Rocco F. III
Published Jun 11, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CNO
Neutral
high confidence
Mentioned
$CNO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The disclosure updates the insider ownership record and can marginally influence sentiment, but it does not introduce new operational, financial, or regulatory information.

02

Market read

A scheduled insider sale of ~$0.45M in CNO shares was filed; sentiment impact is likely small given the 10b5-1 context.

03

What to watch

Traders may still watch for clustering of insider sales across officers/directors or follow-on filings (additional Form 4s) to confirm whether selling is isolated or part of a broader pattern.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-11 (covers sales on 2026-06-10 to 2026-06-11)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for CNO Financial Group, Inc.

Company-level read

Ticker impact

$CNONeutralHigh confidence
Context

CNO Financial CMO Tarasi Rocco F. III sold $449,592 of CNO shares in two open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other news.

Evidence & confidence

The filing is an insider transaction with a stated 10b5-1 plan, and the article provides no new company fundamentals, guidance, or regulatory/legal developments.

Market effects

Minimal; this is company-specific insider activity with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

Because the trades are under a pre-arranged 10b5-1 plan, the selling may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • CNO Financial Group, Inc.

    Subject of the Form 4 insider sale by its Chief Marketing Officer.

  • Tarasi Rocco F. III

    Chief Marketing Officer who sold 9,058 CNO shares in two open-market trades.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as the basis for the insider’s sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$CNOLow

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni